Your browser doesn't support javascript.
loading
Effectiveness and Safety of Dapagliflozin for Black vs White Patients With Chronic Kidney Disease in North and South America: A Secondary Analysis of a Randomized Clinical Trial.
Vart, Priya; Jongs, Niels; Wheeler, David C; Heerspink, Hiddo J L; Langkilde, Anna Maria; Chertow, Glenn M.
Afiliación
  • Vart P; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
  • Jongs N; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
  • Wheeler DC; Department of Renal Medicine, University College London, London, United Kingdom.
  • Heerspink HJL; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
  • Langkilde AM; The George Institute for Global Health, Sydney, Australia.
  • Chertow GM; BioPharmaceuticals R&D, AstraZeneca, Gotherburg, Sweden.
JAMA Netw Open ; 6(4): e2310877, 2023 04 03.
Article en En | MEDLINE | ID: mdl-37103935
This secondary analysis of a randomized clinical trial investigates the relative effectiveness and safety of the sodium-glucose cotransporter-2 inhibitor dapagliflozin for Black vs White patients with chronic kidney disease (CKD) in North and South America.
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Insuficiencia Renal Crónica / Blanco Tipo de estudio: Clinical_trials Idioma: En Revista: JAMA Netw Open Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Insuficiencia Renal Crónica / Blanco Tipo de estudio: Clinical_trials Idioma: En Revista: JAMA Netw Open Año: 2023 Tipo del documento: Article